Extrinsic coagulation pathway

The extrinsic coagulation pathway, also known as the tissue factor pathway, is a critical component of the blood coagulation cascade that initiates rapid clot formation in response to vascular injury. It begins when tissue factor (TF, or factor III), a transmembrane glycoprotein exposed from damaged subendothelial cells, binds circulating factor VII, forming the TF-VIIa complex that activates factor X to factor Xa in a calcium- and phospholipid-dependent manner. This leads into the common pathway, where factor Xa, with cofactor Va, converts prothrombin (factor II) to thrombin, which then cleaves fibrinogen into fibrin to stabilize the platelet plug and prevent excessive blood loss. Physiologically, the pathway is tightly regulated by tissue factor pathway inhibitor (TFPI), which downregulates TF-VIIa and TF-VIIa-Xa complexes to limit initial thrombin generation, while amplification occurs via the intrinsic pathway on platelet surfaces. Dysregulation contributes to thrombotic diseases like deep vein thrombosis or stroke, or bleeding disorders if deficient, making components such as factor VIIa and Xa key intervention points. Drugs targeting this pathway, including monoclonal antibodies against TF or direct oral anticoagulants, aim to prevent pathological clotting but carry bleeding risks.

Other names

Tissue factor pathwayExtrinsic blood coagulation pathwayTissue activation pathway

Inhibition of tissue factor-factor VIIa complex; Blockade of factor Xa activation; Prevention of prothrombin to thrombin conversion